Prostate cancer, BRCA-mutated

Page editor		Section editor
	Laura S. Graham, MD University of Washington Fred Hutchinson Cancer Research Center Seattle, WA LauraGrahamMD		Ali Raza Khaki, MD Stanford University Palo Alto, CA arkhaki

7 regimens on this page 8 variants on this page

Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.

Metastatic castration-resistant

Rucaparib monotherapy

back to top

Regimen

Study	Years of enrollment	Evidence
(TRITON2)	2017-NR	Phase II (RT)

Note: this study is the basis of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.

Targeted therapy

• Rucaparib (Rubraca)

References

1. TRITON2: NCT02952534